Should FCC Approval for 248-Satellite Direct-to-Device Network Require Action From AST SpaceMobile (ASTS) Investors?
-
AST SpaceMobile recently received Federal Communications Commission approval to modify its license and deploy up to 248 low Earth orbit satellites, enabling supplemental coverage from space directly to unmodified mobile devices across the U.S. using low-band 700 MHz and 800 MHz spectrum alongside partners Verizon, AT&T and FirstNet.
-
This ruling not only validates AST SpaceMobile’s interference management and system design alongside terrestrial networks, it also strengthens its ability to pursue country-by-country authorizations that could underpin future global direct-to-device services.
-
We’ll now examine how this expanded FCC authorization for a 248-satellite constellation reshapes AST SpaceMobile’s longer-term investment narrative and risk profile.
Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
AST SpaceMobile Investment Narrative Recap
To own AST SpaceMobile, you have to believe in a global, space based cellular network that can connect everyday phones directly to satellites, and that management can execute a capital intensive rollout without eroding returns. The expanded FCC approval for up to 248 low Earth orbit satellites squarely supports the regulatory side of that thesis, but it does not remove the near term execution risk around manufacturing cadence, launch timing and turning contracted commitments into recurring service revenue.
The most relevant recent development alongside the FCC news is the BlueBird 7 launch mishap, where the satellite was placed into an unsustainably low orbit and will de orbit, with costs expected to be recovered by insurance. While management still targets about 45 satellites in orbit by the end of 2026 and is already producing through BlueBird 32, this incident highlights how launch execution, not just licensing, can influence how quickly key service catalysts arrive.
Yet even with fresh regulatory support, investors should still be aware of how launch delays, cost overruns and constellation utilization could...
Read the full narrative on AST SpaceMobile (it's free!)
AST SpaceMobile's narrative projects $2.1 billion revenue and $2.1 billion earnings by 2028. This requires 385.7% yearly revenue growth and about a $2.4 billion earnings increase from -$303.8 million today.
Uncover how AST SpaceMobile's forecasts yield a $71.51 fair value , a 7% downside to its current price.
Exploring Other Perspectives
Before this FCC decision, the most cautious analysts were already baking in big numbers, such as US$1.9 billion of revenue and US$1.7 billion of earnings by 2029, yet still saw risk in whether tight launch schedules and spectrum use would support those outcomes, which shows just how widely your view on AST SpaceMobile can differ from others.
Explore 48 other fair value estimates on AST SpaceMobile - why the stock might be worth less than half the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
-
A great starting point for your AST SpaceMobile research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
-
Our free AST SpaceMobile research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AST SpaceMobile's overall financial health at a glance.
Want Some Alternatives?
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
-
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 18 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
-
AI is about to change healthcare. These 32 stocks are working on everything from early diagnostics to drug discovery . The best part - they are all under $10b in market cap - there's still time to get in early.
-
Uncover the next big thing with 24 elite penny stocks that balance risk and reward.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASTS .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

